HRP20201506T1 - Uporaba kanabidiolne kiseline u liječenju epilepsije - Google Patents

Uporaba kanabidiolne kiseline u liječenju epilepsije Download PDF

Info

Publication number
HRP20201506T1
HRP20201506T1 HRP20201506TT HRP20201506T HRP20201506T1 HR P20201506 T1 HRP20201506 T1 HR P20201506T1 HR P20201506T T HRP20201506T T HR P20201506TT HR P20201506 T HRP20201506 T HR P20201506T HR P20201506 T1 HRP20201506 T1 HR P20201506T1
Authority
HR
Croatia
Prior art keywords
cbda
effective amount
therapeutically effective
use according
epilepsy
Prior art date
Application number
HRP20201506TT
Other languages
English (en)
Inventor
Colin Stott
Nicholas Jones
Robin Williams
Benjamin Whalley
Original Assignee
GW Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Research Limited filed Critical GW Research Limited
Publication of HRP20201506T1 publication Critical patent/HRP20201506T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (13)

1. Terapijski efikasna količina kanabidiolne kiseline (CBDA) za uporabu u liječenju epilepsije, naznačena time što je CBDA u obliku visoko pročišćenog ekstrakta kanabisa, tako da je CBDA prisutna u više od 98% ukupnog ekstrakta (tež./tež.) ili je proizvedena sintetički.
2. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 1, naznačena time što je epilepsija generalizirana epilepsija.
3. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time što epilepsiju karakteriziraju toničko-klonički napadaji.
4. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što je terapijski efikasna količina najmanje 0,1 mg.
5. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 1, naznačena time što visoko pročišćeni ekstrakt sadrži manje od 1% (tež./tež.) tetrahidrokanabinola (THC) ili tetrahidrokanabinolne kiseline (THCA).
6. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se CBDA koristi istovremeno sa jednim ili više drugih kanabinoida.
7. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 6, naznačena time što se CBDA koristi sa kanabidiolom (CBD).
8. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 7, naznačena time što je odnos CBDA: CBD u opsegu od 9:1 do 1:9 (CBDA: CBD).
9. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se CBDA koristi istovremeno sa jednim ili više drugih antiepileptičkih lijekova (AED).
10. Terapijski efikasna količina CBDA za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time što se CBDA koristi u dozi manjoj od 400 mg.
11. Terapijski efikasna količina CBDA za uporabu prema patentnom zahtjevu 10, naznačena time što se CBDA koristi u dozi od 1 mg do 100 mg.
12. Pripravak za uporabu u liječenju epilepsije koji sadrži terapijski efikasnu količinu kanabidiolne kiseline (CBDA), i jedan ili više farmaceutski prihvatljivih ekscipijenata, naznačena time što je CBDA u obliku visoko pročišćenog ekstrakta kanabisa, tako da je CBDA prisutna u više od 98% ukupnog ekstrakta (tež./tež.) ili je proizvedena sintetički.
13. Pripravak za uporabu prema patentnom zahtjevu 12, koji je formuliran za dostavu u vidu oralne tekuće otopine, čvrste supstance, polu-čvrste supstance, gela, spreja, aerosola, inhalatora, isparivača, klistira ili čepića.
HRP20201506TT 2015-08-10 2020-09-21 Uporaba kanabidiolne kiseline u liječenju epilepsije HRP20201506T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514079.1A GB2541191A (en) 2015-08-10 2015-08-10 Use of cannabinoids in the treatment of epilepsy
EP16747593.8A EP3334422B1 (en) 2015-08-10 2016-07-29 Use of cannabidiolic acid in the treatment of epilepsy
PCT/GB2016/052340 WO2017025712A1 (en) 2015-08-10 2016-07-29 Use of cannabinoids in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
HRP20201506T1 true HRP20201506T1 (hr) 2021-02-05

Family

ID=54200465

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201506TT HRP20201506T1 (hr) 2015-08-10 2020-09-21 Uporaba kanabidiolne kiseline u liječenju epilepsije

Country Status (18)

Country Link
US (2) US11147783B2 (hr)
EP (2) EP3334422B1 (hr)
JP (2) JP6949822B2 (hr)
AU (1) AU2016305545B2 (hr)
CA (1) CA2992802C (hr)
CY (1) CY1123351T1 (hr)
DK (1) DK3334422T3 (hr)
ES (1) ES2820333T3 (hr)
GB (1) GB2541191A (hr)
HR (1) HRP20201506T1 (hr)
HU (1) HUE051476T2 (hr)
LT (1) LT3334422T (hr)
MX (2) MX2018001472A (hr)
PL (1) PL3334422T3 (hr)
PT (1) PT3334422T (hr)
RS (1) RS60852B1 (hr)
SI (1) SI3334422T1 (hr)
WO (1) WO2017025712A1 (hr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
MX2020003004A (es) * 2017-09-19 2020-11-06 Zynerba Pharmaceuticals Inc Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
AU2019251357B2 (en) * 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CA3132856A1 (en) * 2019-04-30 2020-11-05 Elliot Altman Cannabinoid composition comprising cbd and cbda
CN114761572A (zh) 2019-08-27 2022-07-15 赫博利生物科技股份公司 大麻素浓缩物和分离物、获得该大麻素浓缩物和分离物的方法及其用途
US20220304943A1 (en) * 2019-10-28 2022-09-29 Canopy Growth Corporation Flowable cannabinoid compositions having high effective concentrations
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
IL298464A (en) * 2020-05-24 2023-01-01 Asana Bio Group Ltd Compositions of cannabinoids and methods of using them
CA3191486A1 (en) 2020-09-04 2022-03-10 Giovanni VENTURINI DEL GRECO Thc-free cannabinoid concentrate, method of obtaining the same and use thereof
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
AU2022361940A1 (en) * 2021-10-11 2024-03-28 Neurotech International Ltd Compositions and methods for treating neurological disorders
CA3231512A1 (en) * 2021-10-11 2023-04-20 Allan William Cripps Compositions and methods for treating neurological disorders with combination products
US11551799B1 (en) * 2022-04-05 2023-01-10 Green Sky Creations LLC Multi-stage release cannabinoid compositions
CA3237737A1 (en) * 2022-09-12 2024-03-21 Elliot Altman Cannabinoid and omega fatty acid compositions and methods of using
WO2024073812A1 (en) * 2022-10-06 2024-04-11 Neurotech International Ltd Methods for treating paediatric neurological disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
IL157130A0 (en) 2001-02-14 2004-02-08 Gw Pharma Ltd A cannabis based pharmaceutical formulation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
EP1482917B1 (en) 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2004016246A1 (en) 2002-08-14 2004-02-26 Gw Pharma Limited Cannabinoid liquid formulations for mucosal amdinistration
PL226646B1 (pl) 2002-08-14 2017-08-31 Gw Pharma Ltd Botaniczna substancja lekowa
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
US20040110828A1 (en) 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
KR20070089151A (ko) 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
US20080112895A1 (en) 2006-08-04 2008-05-15 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US20080188461A1 (en) 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
CN101040855A (zh) 2007-04-12 2007-09-26 杨喜鸿 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
WO2008144475A1 (en) 2007-05-17 2008-11-27 California Pacific Medical Center Methods and compositions for treating cancer
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
EP2023121A1 (en) 2007-07-06 2009-02-11 Bp Oil International Limited Optical cell
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
CA2698752A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
DK2280687T3 (da) 2008-03-26 2019-05-27 Stichting Sanammad Tyggegummisammensætninger omfattende cannabinoider
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
JP5666574B2 (ja) 2009-06-29 2015-02-12 ベンデル・アナリティカル・ホールディング・ビー.ブイ.Bender Analytical Holding B.V. ポリオキサゾリンおよび生物活性物質を含む薬物送達システム
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
SI2600850T1 (sl) 2010-08-04 2018-12-31 Gruenenthal Gmbh Farmacevtska oblika odmerka, ki zajema 6'-fluoro-(N-metil- ali N,N- dimetil-)-4-fenil-4',9'-dihidro-3'H-spiro(cikloheksan-1,1'-pirano (3,4,B)indol)-4-amin, za zdravljenje nociceptivne bolečine
WO2012033478A1 (en) 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
CA2737447A1 (en) * 2011-04-27 2012-10-27 Antony Paul Hornby Hayley's comet
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
MX2015013202A (es) 2013-03-15 2016-04-07 Biotech Inst Llc Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US9259449B2 (en) 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
KR20170008311A (ko) 2014-05-29 2017-01-23 인시스 파마, 인코포레이티드 안정한 카나비노이드 제형
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US20160000843A1 (en) * 2014-07-01 2016-01-07 MJAR Holdings, LLC High cannabidiol cannabis strains
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
CA2859934A1 (en) * 2014-09-22 2016-03-22 A. Paul Hornby Hayley's comet ii
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
EP3209312A1 (en) 2014-10-21 2017-08-30 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2016084075A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
EP3270896A4 (en) 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
AU2016276563A1 (en) 2015-06-11 2018-01-04 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (MM)
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Also Published As

Publication number Publication date
EP3334422B1 (en) 2020-07-01
CY1123351T1 (el) 2021-12-31
AU2016305545A1 (en) 2018-02-08
JP7303267B2 (ja) 2023-07-04
US20220062211A1 (en) 2022-03-03
AU2016305545B2 (en) 2021-12-09
MX2018001472A (es) 2018-04-24
GB201514079D0 (en) 2015-09-23
HUE051476T2 (hu) 2021-03-01
CA2992802A1 (en) 2017-02-16
MX2021000814A (es) 2021-03-25
EP3334422A1 (en) 2018-06-20
JP2021191797A (ja) 2021-12-16
LT3334422T (lt) 2020-11-25
US20180228751A1 (en) 2018-08-16
ES2820333T3 (es) 2021-04-20
GB2541191A (en) 2017-02-15
JP2018527341A (ja) 2018-09-20
RS60852B1 (sr) 2020-10-30
PL3334422T3 (pl) 2020-12-28
EP3769755B1 (en) 2023-05-24
JP6949822B2 (ja) 2021-10-13
EP3769755A1 (en) 2021-01-27
DK3334422T3 (da) 2020-09-28
SI3334422T1 (sl) 2020-11-30
US11684598B2 (en) 2023-06-27
US11147783B2 (en) 2021-10-19
PT3334422T (pt) 2020-09-29
WO2017025712A1 (en) 2017-02-16
CA2992802C (en) 2023-09-19

Similar Documents

Publication Publication Date Title
HRP20201506T1 (hr) Uporaba kanabidiolne kiseline u liječenju epilepsije
HRP20201325T1 (hr) Uporaba kanabidiola u liječenju kompleksa tuberozne skleroze
HRP20201230T1 (hr) Uporaba kanabinoida u liječenju atoničkih napadaja kod lennox-gastaut sindroma
CO2018013654A2 (es) Composiciones nasales de cannabidiol
MX2023007033A (es) Extractos de cannabis y metodos de preparacion y uso de la misma.
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
NZ726746A (en) Stable cannabinoid formulations
MX2019001286A (es) Composicion de cannabis.
ECSP17085659A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CA2582289C (en) Inhibition of tumour cell migration
GB201111261D0 (en) Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
JP2013523708A5 (hr)
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
US20180338947A1 (en) Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition
MX2021013285A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
CO7310521A2 (es) Composición farmaceútica que tiene fluidez mejorada, agente medicional, y método para la producción y uso del mismo